RBC Reaffirms Outperform on Regeneron (REGN) Ahead of Key COPD Drug Results

finance.yahoo.com/news/rbc-reaffirms-outperform-regeneron-regn-152826680.html

In This Article:
Analyst Brian Abrahams reiterated an Outperform rating and a price target of $943 for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on May 29. The rating comes as Regeneron awaits the findings of a phase III study on the medication candidate itepekimab, which is intended…

This story appeared on finance.yahoo.com, 2025-05-30 15:28:26.
The Entire Business World on a Single Page. Free to Use →